Menu Search
Equities

OncoTherapy Science Inc

30O:DEU

OncoTherapy Science Inc

Actions
  • Price (EUR)0.134
  • Today's Change-0.034 / -20.24%
  • Shares traded0.00
  • 1 Year change-6.94%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year OncoTherapy Science Inc's revenues fell -46.24%from 1.13bn to 610.12m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 15.15% reduction in net income from a loss of 1.12bn to a larger loss of 1.29bn.
Gross margin-32.12%
Net profit margin-234.61%
Operating margin-230.75%
Return on assets-82.71%
Return on equity-116.07%
Return on investment-106.53%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at OncoTherapy Science Inc fell by 589.98m. Cash Flow from Financing totalled 671.37m or 110.04% of revenues. In addition the company used 1.23bn for operations while cash used for investing totalled 33.35m.
Cash flow per share-2.47
Price/Cash flow per share--
Book value per share3.68
Tangible book value per share3.68
More ▼

Balance sheet in JPYView more

OncoTherapy Science Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio3.55
Quick ratio3.11
Total debt/total equity0.0789
Total debt/total capital0.0731
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.